LYMPHOMA, T-CELL, PERIPHERAL
Clinical trials for LYMPHOMA, T-CELL, PERIPHERAL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL, PERIPHERAL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, PERIPHERAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough lymphoma: targeted drug soquelitinib faces standard care in phase 3 trial
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard single-agent treatments in 150 adults with certain types of T-cell lymphoma that have come back or not responded to prior therapy. The goal is to see if soquelitinib can delay cancer progression better than current …
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:30 UTC
-
New hope for rare blood cancer: drug duo aims to keep lymphoma in check
Disease control Recruiting nowThis study tests whether adding the drug tucidinostat to standard chemotherapy (CHOP) can help people with a rare type of lymphoma (PTCL-TFH) live longer without their cancer getting worse. About 224 adults with newly diagnosed disease will be randomly assigned to get either tuci…
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated May 08, 2026 12:01 UTC